Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ching-Chi, Hsieh, Chih-Chia, Ko, Wen-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614993/
https://www.ncbi.nlm.nih.gov/pubmed/34827232
http://dx.doi.org/10.3390/antibiotics10111294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614993/
https://www.ncbi.nlm.nih.gov/pubmed/34827232
http://dx.doi.org/10.3390/antibiotics10111294

Ejemplares similares